Rotarix News and Research

RSS

Cases of rotavirus infections fall by 84% thanks to vaccination

Figures published by Public Health England have shown that the number of diagnosed Rotavirus cases, a highly infectious virus which may cause vomiting and diarrhoea, have dropped by 84% since the introduction of a vaccine to the national childhood immunisation schedule in July 2013.

29 Aug 2016

Study: 40% of U.S. infants from low-income families do not receive rotavirus vaccination

Rotavirus (RV) infection is the leading cause of diarrheal disease in young children worldwide, causing more than half a million deaths of children aged <5 years annually, according to the World Health Organization. There are two safe and effective RV vaccines, pentavalent Rotateq (Merck) and monovalent Rotarix (GSK), yet global coverage remains below 20% of children.

9 Mar 2016

Four out of ten children in Burkina Faso genetically resistant to virus strains

Every year rotavirus causes half a million diarrhoea-related deaths amongst children in developing countries. Existing vaccines provide poor protection. The reason could be a widespread genetic resistance amongst children, according to virologists at Linköping University.

15 Oct 2014

CSIRO to produce antibodies for development of new vaccines against rotavirus

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

18 Jul 2012

RV5 vaccination does not increase risk of intussusception in infants

Although some data have suggested a possible increased risk of intussusception (when a portion of the small or large intestine slides forward into itself, like a telescope) after administration of the pentavalent rotavirus vaccine in infants, an analysis that included almost 800,000 doses administered to U.S. infants found no increased risk of this condition following vaccination, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Celldex third quarter net loss increases to $11.8 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011. Celldex reported a net loss of $11.8 million, or $0.27 per share, for the third quarter of 2011 compared to a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010.

2 Nov 2011

Rotavirus vaccine saved 65,000 hospitalizations and $278 million in healthcare costs: Study

The latest research shows that since the 2006 introduction of routine inoculation against rotavirus -- a leading cause of diarrhea in infants and young children -- almost 65,000 fewer American children have been hospitalized and about $278 million in healthcare costs have been saved.

26 Sep 2011

Vaccinating infants against rotavirus decreases health care use and treatment costs

Vaccinating infants against rotavirus has resulted in dramatic decreases in health care use and treatment costs for diarrhea-related illness in U.S. infants and young children, according to a new study by the Centers for Disease Control and Prevention. The study is published in the current issue of the New England Journal of Medicine.

22 Sep 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Celldex Therapeutics, Inc. today announced that the Company presented initial clinical data on CDX-1401 at the 25th Annual Meeting of the International Society of Biological Therapy of Cancer (iSBTc) in Washington, DC. CDX-1401 is a novel antibody-based targeted cancer vaccine candidate being evaluated as a treatment for patients with melanoma and other cancers that are known to express the tumor antigen NY-ESO-1.

5 Oct 2010

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.

20 Sep 2010

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

This week, the National Advisory Committee on Immunization updated and strengthened its statement related to the use of rotavirus vaccines in Canada. Rotavirus infection is the most common cause of severe gastroenteritis in children under the age of three. The NACI statement now includes Grade A recommendations (good evidence to recommend immunization) for healthy and preterm infants.

21 Jul 2010

Cell Therapeutics' Special Meeting of Shareholders adjourned to June 4, 2010

Cell Therapeutics, Inc. today announced that the Company has adjourned today's Special Meeting of Shareholders to 10:00 am Pacific Daylight Time, Friday, June 4, 2010.

15 May 2010

Miami-area resident charged in $23M HIV infusion Medicare fraud scheme

A Miami-area resident who owned and operated an HIV infusion clinic was arrested today and charged for her alleged participation in a $23 million HIV infusion Medicare fraud scheme, the Departments of Justice and Health and Human Services (HHS) announced.

15 May 2010

Hiru Corporation completes Quarterly Report

Hiru Corporation publishes this Quarterly Report to serve the company's followers, investors and the public as a guidance through the past events and possible outcomes of these events in the upcoming quarter(s).

15 May 2010

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).

15 May 2010

U.S. healthcare practitioners can resume use of Rotarix, says FDA

GlaxoSmithKline announced that the Food and Drug Administration has determined that U.S. healthcare practitioners can resume the use of Rotarix (Rotavirus Vaccine, Live, Oral), effective immediately. This action supersedes the FDA's recommendation from March 22, 2010 and reflects the agency's assessment that the presence of porcine circovirus type 1 in the vaccine poses no safety risk.

15 May 2010

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.

15 May 2010